MX2019007376A - Anticuerpos contra el lif y usos de los mismos. - Google Patents

Anticuerpos contra el lif y usos de los mismos.

Info

Publication number
MX2019007376A
MX2019007376A MX2019007376A MX2019007376A MX2019007376A MX 2019007376 A MX2019007376 A MX 2019007376A MX 2019007376 A MX2019007376 A MX 2019007376A MX 2019007376 A MX2019007376 A MX 2019007376A MX 2019007376 A MX2019007376 A MX 2019007376A
Authority
MX
Mexico
Prior art keywords
antibodies against
lif
against lif
antibodies
cancer
Prior art date
Application number
MX2019007376A
Other languages
English (en)
Inventor
Seoane Suarez Joan
Fransson Johan
Anido Folgueira Judit
Julien Jean-Philippe
Raman Swetha
Original Assignee
Mosaic Biomedicals S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaic Biomedicals S L U filed Critical Mosaic Biomedicals S L U
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of MX2019007376A publication Critical patent/MX2019007376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se describen los anticuerpos que se dirigen al factor inhibidor de la leucemia (LIF). En el presente documento también se describen los usos de estos anticuerpos para el tratamiento de cáncer.
MX2019007376A 2016-12-19 2017-12-18 Anticuerpos contra el lif y usos de los mismos. MX2019007376A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (1)

Publication Number Publication Date
MX2019007376A true MX2019007376A (es) 2020-02-07

Family

ID=67138942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007376A MX2019007376A (es) 2016-12-19 2017-12-18 Anticuerpos contra el lif y usos de los mismos.

Country Status (20)

Country Link
US (2) US11390670B2 (es)
EP (2) EP4321219A3 (es)
JP (3) JP7100056B2 (es)
KR (2) KR20230125099A (es)
AU (1) AU2017381585A1 (es)
BR (1) BR112019012691A2 (es)
CA (1) CA3047528A1 (es)
CL (2) CL2019001717A1 (es)
DK (1) DK3555132T3 (es)
ES (1) ES2971126T3 (es)
FI (1) FI3555132T3 (es)
HR (1) HRP20240195T8 (es)
HU (1) HUE065241T2 (es)
IL (2) IL294088B2 (es)
LT (1) LT3555132T (es)
MX (1) MX2019007376A (es)
PL (1) PL3555132T3 (es)
RS (1) RS65187B1 (es)
SA (1) SA519402119B1 (es)
SI (1) SI3555132T1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019251289B2 (en) 2018-04-12 2024-01-18 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
US20230050773A1 (en) * 2019-12-04 2023-02-16 Medimmune Limited Antibodies against lif and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH11504332A (ja) 1995-04-24 1999-04-20 ジェネンテク・インコーポレイテッド 白血病抑制因子およびエンドテリンアンタゴニストの用途
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
CA2605723A1 (en) * 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20110135645A1 (en) 2006-10-04 2011-06-09 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CN110256560A (zh) 2013-03-11 2019-09-20 建新公司 通过糖工程的位点特异性抗体-药物偶联
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3037434B1 (en) 2013-08-20 2018-07-18 Japan Science and Technology Agency Human antibody kappa type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
US20160237158A1 (en) 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
AU2014331923B2 (en) 2013-10-09 2020-02-06 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
AU2019251289B2 (en) * 2018-04-12 2024-01-18 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
WO2019243898A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods for improving response to anti-lif antibody treatment in individuals with cancer

Also Published As

Publication number Publication date
KR20230125099A (ko) 2023-08-28
FI3555132T3 (fi) 2024-02-08
US11390670B2 (en) 2022-07-19
JP7100056B2 (ja) 2022-07-12
CA3047528A1 (en) 2018-06-28
KR20190122652A (ko) 2019-10-30
HUE065241T2 (hu) 2024-05-28
BR112019012691A2 (pt) 2019-11-19
PL3555132T3 (pl) 2024-04-22
IL294088A (en) 2022-08-01
EP4321219A2 (en) 2024-02-14
CN111868086A (zh) 2020-10-30
EP3555132A1 (en) 2019-10-23
KR102599557B1 (ko) 2023-11-07
HRP20240195T8 (hr) 2024-05-24
JP7459173B2 (ja) 2024-04-01
EP3555132B1 (en) 2023-11-15
LT3555132T (lt) 2024-02-26
CL2019001717A1 (es) 2020-02-28
IL267450B (en) 2022-07-01
DK3555132T3 (da) 2024-02-05
EP4321219A3 (en) 2024-05-15
SA519402119B1 (ar) 2023-02-19
SI3555132T1 (sl) 2024-04-30
CL2021000950A1 (es) 2021-11-26
AU2017381585A1 (en) 2019-07-18
US20190352389A1 (en) 2019-11-21
IL267450A (en) 2019-08-29
HRP20240195T1 (hr) 2024-04-26
JP2022130632A (ja) 2022-09-06
ES2971126T3 (es) 2024-06-03
JP2024075682A (ja) 2024-06-04
IL294088B1 (en) 2023-06-01
US20230042095A1 (en) 2023-02-09
IL294088B2 (en) 2023-10-01
RS65187B1 (sr) 2024-03-29
JP2020512388A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
EP3576781A4 (en) NEOANTIGENS AND THEIR USES IN CANCER TREATMENT
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
NZ738008A (en) Tigit-binding agents and uses thereof
MY191581A (en) Anti-pd-1 antibodies
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
MX2020006297A (es) Variantes de cd19.
EP3273983A4 (en) Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
WO2016205737A3 (en) Tumor immunotherapy
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
WO2019220204A3 (en) Antibodies against lif and dosage forms thereof
MX2019007376A (es) Anticuerpos contra el lif y usos de los mismos.
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MEDIMMUNE LIMITED